Sequoia Financial Advisors LLC Sells 310 Shares of Novo Nordisk A/S (NYSE:NVO)

Sequoia Financial Advisors LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 1.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 31,519 shares of the company’s stock after selling 310 shares during the period. Sequoia Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,753,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in NVO. Price T Rowe Associates Inc. MD grew its position in shares of Novo Nordisk A/S by 10.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock valued at $1,102,857,000 after purchasing an additional 823,036 shares during the period. Envestnet Asset Management Inc. lifted its stake in Novo Nordisk A/S by 1.4% in the second quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock valued at $607,242,000 after buying an additional 58,935 shares in the last quarter. GQG Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 654.6% in the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock valued at $466,485,000 after buying an additional 3,151,584 shares during the period. Raymond James & Associates increased its position in shares of Novo Nordisk A/S by 1.0% during the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after acquiring an additional 36,223 shares in the last quarter. Finally, 1832 Asset Management L.P. raised its stake in shares of Novo Nordisk A/S by 7.8% in the 1st quarter. 1832 Asset Management L.P. now owns 2,373,029 shares of the company’s stock valued at $304,697,000 after purchasing an additional 172,003 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on NVO. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Trading Down 0.7 %

NYSE NVO opened at $115.70 on Thursday. The company has a market cap of $519.21 billion, a PE ratio of 39.62, a PEG ratio of 1.54 and a beta of 0.42. Novo Nordisk A/S has a 12 month low of $92.94 and a 12 month high of $148.15. The stock has a 50 day moving average of $127.52 and a 200-day moving average of $131.50. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The firm had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a dividend of $0.5126 per share. This represents a yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.66%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.